article thumbnail

Gender-affirming hormone therapy may increase risk of high blood pressure

Scienmag

Hypertension Journal report DALLAS, April 19, 2021 — Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in Hypertension, an American Heart Association journal.

article thumbnail

New hormone therapies for hot flashes offer enhanced benefits and minimized risk

Scienmag

Yale physician to discuss the most promising developments in estrogen therapy, including new fetal estrogens, during the 2020 NAMS Virtual Annual Meeting Pre-Meeting Symposium CLEVELAND, Ohio (September 28, 2020)–Hormone therapy remains the best proven method for managing menopause symptoms such as hot flashes.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New treatment can improve cardiac pump function in patients with heart failure

Medical Xpress

A clinical study by researchers at Karolinska Institutet and Karolinska University Hospital in Sweden shows that the hunger hormone ghrelin can increase the heart's pump capacity in patients with heart failure. The results have been published in the European Heart Journal.

article thumbnail

Heart Conditions Could Raise Risk of Torn Aorta During Pregnancy

The Pharma Data

22, 2020 — Pregnancy can increase the risk of a rare, dangerous heart condition called aortic dissection, researchers report. Researchers analyzed data from 29 women who were unexpectedly hospitalized for aortic dissection while pregnant. 14 in the journal JAMA Cardiology. THURSDAY, Oct. Patients require lifesaving care.

article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

Bayer’s research and development pipeline continues to grow as the company is building on its existing competencies, such as the expertise around small molecules, while expanding into new modalities, including cell and gene therapies. “We

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. To overcome this, Glucagon, a hormone in the body, helps the liver to quickly increase blood sugar levels. mg and norethindrone acetate (0.5 mg) in the US and Canada. The post A USD 4.2

Trials 52
article thumbnail

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

The Pharma Data

. “When our specialties collaborate, we give our patients the best chance of success – which is highlighted in our professional society guidelines, including those from the American Diabetes Association and the American College of Cardiology.” This survey was conducted online within the U.S. The survey included 1,000 U.S.

Nurses 52